Launching a new era of connected healthcare in Qingdao
Tunstall Australasia and Revlis Biotech are proud to announce the imminent launch of the new Qingdao Connected Healthcare Centre in China.
The Centre aims to revolutionise healthcare across Asia with the introduction of connected health, supporting health monitoring for aged care in response to China’s rapidly ageing population.
Tunstall Australasia Managing Director Lyn Davies recently attended the International Symposium on Parallel Care for Smart Ageing at the Connected Healthcare Centre and was pleased with the event’s success.
“Hosted by the Qingdao Academy of Intelligent Industries, the symposium attracted over 40 government officials and attendees were impressed with the connected healthcare initiative,” said Ms Davies.
“China’s ageing population requires effective and integrated healthcare, and the launch of the Centre will allow the provision of such solutions,” she said.
As part of the symposium, Tunstall Group Chief Information Officer Geoff Feakes and Revlis’ nurse Eve, led a demonstration of the connected healthcare technologies encompassed within the Centre.
“Throughout the symposium, we showcased Tunstall’s ICP patient management systems in the simple Chinese language versions developed specifically for Revlis,” said Mr Feakes.
“We demonstrated how connected health peripheral devices, including the Revlis Cmate® ECG, integrate with the Tunstall ICP system and how the connected health solution works for both patients and clinicians.
“Attendees were quite impressed with the clarity of the video conferencing capabilities from China to Australia, and could see great benefit in the ability to conduct health evaluations remotely via video conference,” he said.
Revlis Biotech’s Chief Operating Officer Martin Chang said he appreciated Tunstall’s continued support throughout the symposium.
“With the support of Tunstall, we aim to reach 32,000 connected health patients and 16,000 connected care clients by 2019,” said Mr Chang.
“This is the first people-centred, integrated healthcare service of its kind in China, and one that the aged care market greatly needs.
“Thanks to Tunstall’s management software, the Centre will be able to support a range of clients, whether they require connected care or connected health solutions, hopefully alleviating some of the strain on China’s healthcare system,” he said.
Revlis expects to officially launch the Connected Healthcare Centre in early 2017.
For further information about Tunstall's connected healthcare solutions, please call 1800 603 377 or visit www.tunstallhealthcare.com.au
About Revlis Biotech
Revlis Biotech Co., Ltd was established in 2003. In the early years, Revlis focused on the business of cosmetic products. In addition to cooperated with Japan KANSAI-KOSO Co,. Ltd., Revlis became the sole distributor of Germany Burnus GmbH in Greater China region with its brands KAMILL and GLYSOLID.
In 2008, the IT health sector was established and concentrated on research and development of Cmate® Portable ECG and Chlorophyll Energy. Revlis combined domestic industry, government, academia, research and other resources, which at the same time had enabled it to strengthen our own R&D capabilities. As a result, Cmate® Portable ECG device not only had been certificated by CE, ISO quality authorization, but also obtained certifications from Taiwan, China and Australia. Moreover, the technique of Chlorophyll Energy was patented by many countries.
In 2010, the branch company Revlis (Shanghai) Trading Co., Ltd. was established as an important forward base in the Greater China market. After making every effort, Revlis cooperated with Lenovo Group and involved in the field of medical applications and cloud services Telemedicine. In 2015, another branch company, LianWei (Shanghai) Medtech Co., Ltd was established.
Revlis continually strives for outstanding quality in order to realize our ideals "Healthy, Pretty and Long-lived! Let dreams higher, make lives better!"